Anaplastic pleomorphic xanthoastrocytoma with epithelioid morphology misdiagnosed and treated as melanoma
Neurooncol Adv
.
2022 Jan 25;4(1):vdac009.
doi: 10.1093/noajnl/vdac009.
eCollection 2022 Jan-Dec.
Authors
Mario M Dorostkar
1
,
Dinah Konnerth
2
,
Maximilian Niyazi
2
3
,
Niklas Thon
4
,
Max Schlaak
5
,
Kinan Hayani
5
,
Anne Guertler
5
Affiliations
1
Center for Neuropathology and Prion Research, Ludwig-Maximilian University (LMU), Munich, Germany.
2
Department of Radiation Oncology, University Hospital of Munich, Ludwig-Maximilian University (LMU), Munich, Germany.
3
German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
4
Department of Neurosurgery, University Hospital of Munich, Ludwig-Maximilian University (LMU), Munich, Germany.
5
Department of Dermatology and Allergy, University Hospital of Munich, Ludwig-Maximilian University (LMU), Munich, Germany.
PMID:
35198980
PMCID:
PMC8859830
DOI:
10.1093/noajnl/vdac009
No abstract available
Keywords:
BRAF and MEK inhibitors; BRAF mutation; astrocytoma; pleomorphic xanthoastrocytoma.